IL-17 monoclonal antibody (interleukin 17 monoclonal antibody) is not currently used in cancer treatment, and is mainly used in the treatment of patients with moderate to severe psoriasis. The common IL-17 monoclonal antibodies include Skucilumab and Budalumab. 1. Skuclizumab: It is commonly used in the treatment of psoriasis, ankylosing spondylitis, rheumatism, rheumatoid arthritis and other diseases. The drug is most commonly associated with adverse skin reactions, and should be used with caution in children, pregnant women and pregnant women. 2. Budalumab: patients with psoriasis treated with it have a generally lower incidence of malignant tumors. It is the only correlation between this type of monoclonal antibody and cancer, and there is no data about its treatment of cancer for the time being. If you are suffering from cancer, you should actively cooperate with the doctor’s treatment and do not stop the treatment, with a view to prolonging the patient’s life and improving the quality of life as much as possible.